Literature DB >> 26537494

Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review.

Timothy Vollmer1, Lynn Huynh2, Caroline Kelley2, Philip Galebach2, James Signorovitch3, Allitia DiBernardo4, Rahul Sasane4.   

Abstract

Patients with multiple sclerosis (MS) experience varying rates of brain volume (BV) loss ranging from 0.5 to 1.5 % per year. In addition, 66 % of patients with MS experience cognitive impairment, resulting in impact on daily activities. A systematic literature review (2003-2013) was conducted to identify all studies reporting a relationship between whole BV measures and selected patient outcomes measuring cognition, including the Symbol Digit Modalities Test (SDMT), Paced Auditory Serial Addition Test (PASAT) and MS Functional Composite (MSFC) scores. We identified 18 studies reporting associations between whole BV and cognitive outcomes. Six studies (33 %) examined the association between BV and SDMT; all six studies reported that BV loss (BVL) was significantly associated with a decline in SDMT scores (all p < 0.05). Among 14 studies (78 %) that examined the association between BV and PASAT scores, 12 (86 %) found a significant relationship between BVL and lower PASAT scores (all p < 0.05). Of the seven studies (39 %) that looked at BV and MSFC, six studies (86 %) found BVL significantly associated with lower MSFC scores (all p < 0.05). Our study demonstrated that BVL is associated with declines in cognition in MS patients across several cognition measures. The results of this study suggest that BV is a critical component of disease activity and progression in MS and has implications for treatment decisions to minimize BVL and preserve cognitive functioning.

Entities:  

Keywords:  Brain volume loss; Cognition; Multiple sclerosis; Patient outcomes; Systematic literature review

Mesh:

Year:  2015        PMID: 26537494     DOI: 10.1007/s10072-015-2400-1

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  49 in total

1.  Validity of a computerized version of the symbol digit modalities test in multiple sclerosis.

Authors:  Nadine Akbar; Kimia Honarmand; Nancy Kou; Anthony Feinstein
Journal:  J Neurol       Date:  2010-10-06       Impact factor: 4.849

2.  Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis.

Authors:  Maria Pia Sormani; Douglas L Arnold; Nicola De Stefano
Journal:  Ann Neurol       Date:  2014-01-02       Impact factor: 10.422

3.  MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability.

Authors:  D K B Li; U Held; J Petkau; M Daumer; F Barkhof; F Fazekas; J A Frank; L Kappos; D H Miller; J H Simon; J S Wolinsky; M Filippi
Journal:  Neurology       Date:  2006-05-09       Impact factor: 9.910

4.  Evolving expectations around early management of multiple sclerosis.

Authors:  Ralf Gold; Jerry S Wolinsky; Maria Pia Amato; Giancarlo Comi
Journal:  Ther Adv Neurol Disord       Date:  2010-11       Impact factor: 6.570

5.  Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis.

Authors:  R H C Lazeron; J B Boringa; M Schouten; B M J Uitdehaag; E Bergers; J Lindeboom; M I Eikelenboom; P H Scheltens; F Barkhof; C H Polman
Journal:  Mult Scler       Date:  2005-10       Impact factor: 6.312

6.  Defining multiple sclerosis disease activity using MRI T2-weighted difference imaging.

Authors:  M A Lee; S Smith; J Palace; P M Matthews
Journal:  Brain       Date:  1998-11       Impact factor: 13.501

7.  Characteristics of neurological and cognitive status in patients with multiple sclerosis in relation to the location and volumes of demyelination foci and the severity of brain atrophy.

Authors:  K K Mineev; L N Prakhova; A G Il'ves; G V Kataeva; A M Petrov; T N Reznikova; A V Pozdnyakov; I D Stolyarov
Journal:  Neurosci Behav Physiol       Date:  2009-01

8.  Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden.

Authors:  Ralph H B Benedict; Bianca Weinstock-Guttman; Inna Fishman; Jitendra Sharma; Christopher W Tjoa; Rohit Bakshi
Journal:  Arch Neurol       Date:  2004-02

9.  Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis.

Authors:  Maria Pia Amato; Emilio Portaccio; Benedetta Goretti; Valentina Zipoli; Marco Battaglini; Maria Letizia Bartolozzi; Maria Laura Stromillo; Leonello Guidi; Gianfranco Siracusa; Sandro Sorbi; Antonio Federico; Nicola De Stefano
Journal:  Arch Neurol       Date:  2007-08

Review 10.  Pathogenesis of axonal and neuronal damage in multiple sclerosis.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Neurology       Date:  2007-05-29       Impact factor: 9.910

View more
  19 in total

1.  Advances in clinical neurology through the journal "Neurological Sciences" (2015-2016).

Authors:  Ilaria Di Donato; Antonio Federico
Journal:  Neurol Sci       Date:  2017-01       Impact factor: 3.307

Review 2.  Effect of exercise therapy on quality of life of patients with multiple sclerosis in Iran: a systematic review and meta-analysis.

Authors:  Abolhassan Afkar; Asieh Ashouri; Marjan Rahmani; Abdolhosein Emami Sigaroudi
Journal:  Neurol Sci       Date:  2017-07-07       Impact factor: 3.307

3.  Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing-remitting multiple sclerosis.

Authors:  Dawn W Langdon; Davorka Tomic; Iris-Katharina Penner; Pasquale Calabrese; Gary Cutter; Dieter A Häring; Frank Dahlke; Ludwig Kappos
Journal:  Eur J Neurol       Date:  2021-10-12       Impact factor: 6.288

4.  Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study.

Authors:  Lars G Hvid; Egon Stenager; Ulrik Dalgas
Journal:  J Neurol       Date:  2022-04-28       Impact factor: 6.682

5.  Pain, cognition and quality of life associate with structural measures of brain volume loss in multiple sclerosis.

Authors:  Nora E Fritz; Snehashis Roy; Jennifer Keller; Jerry Prince; Peter A Calabresi; Kathleen M Zackowski
Journal:  NeuroRehabilitation       Date:  2016-10-14       Impact factor: 2.138

6.  Reliability and Validity of a Danish Version of the Multiple Sclerosis Neuropsychological Screening Questionnaire.

Authors:  Tobias Sejbæk; Morten Blaabjerg; Pippi Sprogøe; Mads Ravnborg
Journal:  Int J MS Care       Date:  2018 Jan-Feb

Review 7.  Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.

Authors:  Thomas Berger; Irina Elovaara; Sten Fredrikson; Chris McGuigan; Lucia Moiola; Kjell-Morten Myhr; Celia Oreja-Guevara; Igor Stoliarov; Uwe K Zettl
Journal:  CNS Drugs       Date:  2017-01       Impact factor: 5.749

Review 8.  The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis.

Authors:  Maria A Rocca; Giancarlo Comi; Massimo Filippi
Journal:  Front Neurol       Date:  2017-09-04       Impact factor: 4.003

9.  The Effect of 20 Minutes Scuba Diving on Cognitive Function of Professional Scuba Divers.

Authors:  Seyedeh Faezeh Pourhashemi; Hedayat Sahraei; Gholam Hossein Meftahi; Boshra Hatef; Bahareh Gholipour
Journal:  Asian J Sports Med       Date:  2016-08-30

10.  Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis-A Longitudinal Observational Study.

Authors:  Ester Riepl; Steffen Pfeuffer; Tobias Ruck; Hubertus Lohmann; Heinz Wiendl; Sven G Meuth; Andreas Johnen
Journal:  Front Neurol       Date:  2018-01-16       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.